Compare · ABT vs OCS
ABT vs OCS
Side-by-side comparison of Abbott Laboratories (ABT) and Oculis Holding AG (OCS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and OCS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $152.90B, about 181.7x OCS ($841.4M).
- Over the past year, ABT is down 34.3% and OCS is down 24.8% - OCS leads by 9.5 points.
- OCS has been more active in the news (6 items in the past 4 weeks vs 4 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 10 for OCS).
- Company
- Abbott Laboratories
- Oculis Holding AG
- Price
- $87.73+2.52%
- $14.59-35.13%
- Market cap
- $152.90B
- $841.4M
- 1M return
- -3.20%
- -46.77%
- 1Y return
- -34.34%
- -24.79%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 6
- Recent ratings
- 25
- 10
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
- New insider Conroy Kevin T claimed ownership of 131,451 units of Common shares without par value (SEC Form 3)
- Director Stratton John G was granted 2,286 units of Common shares without par value, increasing direct ownership by 12% to 21,319 units (SEC Form 4)
Latest OCS
- Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
- Guggenheim initiated coverage on Oculis Holding AG with a new price target
- SEC Form 6-K filed by Oculis Holding AG
- Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
- Oculis Reports Q1 2026 Financial Results and Provides Company Update
- SEC Form 6-K filed by Oculis Holding AG
- Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
- Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
- Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- Amendment: SEC Form SCHEDULE 13G/A filed by Oculis Holding AG